Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.51 |
| ▸ | PNMT | P11086 | 7/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26684149 | 1.00 | DDB1 (0.53) | DDB1CRBNHTR6PNMTADRA2A | |
| Hydrochloric Acid SCHEMBL25338136 | 0.99 | DDB1 (0.51) | DDB1CRBNHTR6PNMTADRA2A | |
| Hydrochloric Acid SCHEMBL29506976 | 0.99 | DDB1 (0.51) | DDB1CRBNHTR6PNMTADRA2A | |
| SCHEMBL22144444 | 0.94 | DDB1 (0.53) | DDB1CRBNHTR6F10DRD2 | |
| SCHEMBL30201617 | 0.94 | DDB1 (0.53) | DDB1CRBNHTR6F10DRD2 | |
| Hydrochloric Acid SCHEMBL29507046 | 0.93 | DDB1 (0.51) | DDB1CRBNHTR6F10DRD2 | |
| Hydrochloric Acid SCHEMBL25431522 | 0.93 | DDB1 (0.51) | DDB1CRBNHTR6F10DRD2 | |
| SCHEMBL30449553 | 0.90 | CRBN (0.57) | DDB1CRBNHTR6 | |
| SCHEMBL26683732 | 0.90 | CRBN (0.57) | DDB1CRBNHTR6 | |
| Trifluoroacetic Acid SCHEMBL31630928 | 0.89 | HTR6 (0.46) | DDB1CRBNHTR6F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| CN-116249554-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-06-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | DDB1 4162/4885CRBN 2312/4885HTR6 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.